MUBODINA® is a preclinical product candidate in discovery phase as a new fully human recombinant antibody with anti-inflammatory potential. The antibody is currently in preclinical development as a treatment for typical hemolytic uremic syndrome (tHUS).
tHUS is a rare and complex disease caused by bacteria and viral infections with high morbidity characterized by progressive renal failure associated with microangiopathic hemolytic anemia and thrombocytopenia, caused by excessive activation of the inflammatory complement system.
MUBODINA® binds to complement component C5, which is the final component in the pro-inflammatory cascade activated in tHUS.
C5 is an ideal target since its neutralization inhibits the activation of the terminal sequence of both classical and alternative pathways without interfering with the opsonizing activity of the early components.
